Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

VYNE Therapeutics (VYNE) Asset Writedowns and Impairment (2020 - 2021)

VYNE Therapeutics' Asset Writedowns and Impairment history spans 2 years, with the latest figure at $1.6 million for Q4 2021.

For Q4 2021, Asset Writedowns and Impairment changed N/A year-over-year to $1.6 million; the TTM value through Dec 2021 reached $3.2 million, down 94.11%, while the annual FY2021 figure was $1.6 million, 97.06% down from the prior year.
Asset Writedowns and Impairment reached $1.6 million in Q4 2021 per VYNE's latest filing, roughly flat from $1.6 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $54.3 million in Q2 2020 to a low of $1.6 million in Q3 2021.